These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
270 related articles for article (PubMed ID: 11933860)
21. End-stage nonalcoholic fatty liver disease: evaluation of pathomorphologic features and relationship to cryptogenic cirrhosis from study of explant livers in a living donor liver transplant program. Nayak NC; Vasdev N; Saigal S; Soin AS Hum Pathol; 2010 Mar; 41(3):425-30. PubMed ID: 19954815 [TBL] [Abstract][Full Text] [Related]
22. The histologic spectrum of nonalcoholic fatty liver disease. Contos MJ; Choudhury J; Mills AS; Sanyal AJ Clin Liver Dis; 2004 Aug; 8(3):481-500, vii. PubMed ID: 15331059 [TBL] [Abstract][Full Text] [Related]
23. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Yalamanchili K; Saadeh S; Klintmalm GB; Jennings LW; Davis GL Liver Transpl; 2010 Apr; 16(4):431-9. PubMed ID: 20373454 [TBL] [Abstract][Full Text] [Related]
29. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Salomao M; Yu WM; Brown RS; Emond JC; Lefkowitch JH Am J Surg Pathol; 2010 Nov; 34(11):1630-6. PubMed ID: 20975341 [TBL] [Abstract][Full Text] [Related]
30. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Hossain N; Afendy A; Stepanova M; Nader F; Srishord M; Rafiq N; Goodman Z; Younossi Z Clin Gastroenterol Hepatol; 2009 Nov; 7(11):1224-9, 1229.e1-2. PubMed ID: 19559819 [TBL] [Abstract][Full Text] [Related]
31. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Verma S; Jensen D; Hart J; Mohanty SR Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360 [TBL] [Abstract][Full Text] [Related]
32. Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels? McPherson S; Anstee QM; Henderson E; Day CP; Burt AD Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):652-8. PubMed ID: 23325287 [TBL] [Abstract][Full Text] [Related]
34. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Fracanzani AL; Valenti L; Bugianesi E; Andreoletti M; Colli A; Vanni E; Bertelli C; Fatta E; Bignamini D; Marchesini G; Fargion S Hepatology; 2008 Sep; 48(3):792-8. PubMed ID: 18752331 [TBL] [Abstract][Full Text] [Related]
35. Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity. Fracanzani AL; Valenti L; Bugianesi E; Vanni E; Grieco A; Miele L; Consonni D; Fatta E; Lombardi R; Marchesini G; Fargion S J Hepatol; 2011 Jun; 54(6):1244-9. PubMed ID: 21145841 [TBL] [Abstract][Full Text] [Related]
36. Late nonalcoholic fatty liver disease with cirrhosis: a pathologic case of lost or mistaken identity. Lefkowitch JH; Morawski JL Semin Liver Dis; 2012 Feb; 32(1):92-8. PubMed ID: 22418891 [TBL] [Abstract][Full Text] [Related]
37. From nonalcoholic fatty liver to nonalcoholic steatohepatitis and cirrhosis in HIV-infected patients: diagnosis and management. Lemoine M; Serfaty L; Capeau J Curr Opin Infect Dis; 2012 Feb; 25(1):10-6. PubMed ID: 22183113 [TBL] [Abstract][Full Text] [Related]